ArticleDiabetes2013
Fecal microbiota composition differs between children with β-cell autoimmunity and those without.
Article in Diabetes, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03032354 (Effect of Lactobacillus Rhamnosus GG and Bifidobacterium Lactis BB 12 on Beta-cell Function in Children With Newly Diagnosed Type 1 Diabetes - a Randomized Controlled Trial), which is not on this map. Cited by 309 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Lactobacillus Rhamnosus GG and Bifidobacterium Lactis BB 12 on Beta-cell Function in Children With Newly Diagnosed Type 1 Diabetes - a Randomized Controlled Trial
Who cites it
309 citing papers in PubMed, 8 syntheses or guidelines pooled it, 545 citations in OpenAlex.
- Changes in Gut Microbiota and Multiple Sclerosis: A Systematic Review.International journal of environmental research and public health · 2023Pooled it
- Gut microbiome and blood glucose control in type 1 diabetes: a systematic review.Frontiers in endocrinology · 2023Pooled it
- Fecal microbiota transplantation treatment of autoimmune-mediated type 1 diabetes: A systematic review.Frontiers in cellular and infection microbiology · 2022Pooled it
- Safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- The effect of probiotics, prebiotics or synbiotics on metabolic outcomes in individuals with diabetes: a systematic review and meta-analysis.Diabetologia · 2021Pooled it
- Pooled it
- Gut Microbiota Profile in Patients with Type 1 Diabetes Based on 16S rRNA Gene Sequencing: A Systematic Review.Disease markers · 2020Pooled it
- Dietary Factors and Modulation of Bacteria Strains ofNutrients · 2019Pooled it
- Probiotic normalization of systemic inflammation in siblings of type 1 diabetes patients: an open-label pilot study.Scientific reports · 2022Trial
- Lack of effect ofBMJ open diabetes research & care · 2021Trial
- Trial
- Stool microbiome, pH and short/branched chain fatty acids in infants receiving extensively hydrolyzed formula, amino acid formula, or human milk through two months of age.BMC microbiology · 2020Trial
- Effect of High versus Low Dairy Consumption on the Gut Microbiome: Results of a Randomized, Cross-Over Study.Nutrients · 2020Trial
- Oral butyrate does not affect innate immunity and islet autoimmunity in individuals with longstanding type 1 diabetes: a randomised controlled trial.Diabetologia · 2020Trial
- Diet, gut microbiome, and type 1 diabetes: from risk to translational opportunity.Gut microbes · 2026Review
- From Inclusion Complexes to Metabolic Signaling: The Emerging Role of γ-Cyclodextrin in Gut Microbiota and Metabolic Regulation.Molecules (Basel, Switzerland) · 2026Review
- Exploring community-level gut health amidst COVID-19 pandemic: a proposed application of longitudinal wastewater surveillance.Environmental science and pollution research international · 2026Article
- The Role of Microbiota in Type 1 Diabetes: Insights into Dysbiosis and Immune Interactions.Nutrients · 2026Review
- Gut Microbiota and Autoimmune Diseases: The Therapeutic Potential of Probiotics.Current microbiology · 2026Review
- Intestinal Microbiota in Diabetes-Does the Pathomechanism and Diversity Depend on the Type of Diabetes and Coexisting Metabolic Disorders?Journal of clinical medicine · 2026Review
249 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of the intestinal microbiota as a regulator of autoimmune diabetes in animal models is well-established, but data on human type 1 diabetes are tentative and based on studies including only a few study subjects. To exclude secondary effects of diabetes and HLA risk genotype on gut microbiota, we compared the intestinal microbiota composition in children with at least two diabetes-associated autoantibodies (n = 18) with autoantibody-negative children matched for age, sex, early feeding history, and HLA risk genotype using pyrosequencing. Principal component analysis indicated that a low abundance of lactate-producing and butyrate-producing species was associated with β-cell autoimmunity. In addition, a dearth of the two most dominant Bifidobacterium species, Bifidobacterium adolescentis and Bifidobacterium pseudocatenulatum, and an increased abundance of the Bacteroides genus were observed in the children with β-cell autoimmunity. We did not find increased fecal calprotectin or IgA as marker of inflammation in children with β-cell autoimmunity. Functional studies related to the observed alterations in the gut microbiome are warranted because the low abundance of bifidobacteria and butyrate-producing species could adversely affect the intestinal epithelial barrier function and inflammation, whereas the apparent importance of the Bacteroides genus in development of type 1 diabetes is insufficiently understood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.